Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor-positive breast cancer: A TEAM study analysis

Oncologist

Volumn 17, Issue 1, 2012, Pages 55-63

  van de water, Willemien ^a   Bastiaannet, Esther ^a   Hille, Elysée T M ^a   Meershoek Klein Kranenbarg, Elma M ^a   Putter, Hein ^a   Seynaeve, Caroline M ^b   Paridaens, Robert ^c   de Craen, Anton J M ^a   Westendorp, Rudi G J ^a   Liefers, Gerrit Jan ^a   van de Veldea, Cornelis J H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Breast cancer; Elderly; Endocrine therapy; Persistence

Indexed keywords

ESTROGEN RECEPTOR; EXEMESTANE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HORMONE RECEPTOR POSITIVE BREAST CANCER; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; POSTMENOPAUSE; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84856255135     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0037     Document Type: Article

References (34)

1. Jemal A, Bray F, CenterMMet al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687-1717.
3. Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology 2006; 71:1-9.
4. Fink AK, Gurwitz J, RakowskiWet al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 2004;22:3309-3315.
5. Barron TI, Connolly R, Bennett K et al. Early discontinuation of tamoxifen: A lesson for oncologists. Cancer 2007;109:832-839.
6. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001; 19:322-328.
7. Owusu C, Buist DS, Field TS et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008;26:549-555.
8. Ruddy KJ, Partridge AH. Adherence with adjuvant hormonal therapy for breast cancer. Ann Oncol 2009;20:401-402.
9. Wildiers H, Kunkler I, Biganzoli L et al. Management of breast cancer in elderly individuals: Recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007;8:1101-1115.
10. Hillner BE, Mandelblatt J. Caring for older women with breast cancer: Can observational research fill the clinical trial gap? J Natl Cancer Inst 2006;98:660-661.
11. Van de Velde CJ, Rea D, Seynaeve C et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomised phase 3 trial. Lancet 2011;377:321-331.
12. Van Nes JG, Seynaeve C, Jones S et al. Variations in locoregional therapy in postmenopausal patients with early breast cancer treated in different countries. Br J Surg 2010;97:671-679.
13. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1:710-719.
14. Dezentjé VO, van Blijderveen NJ, Gelderblom H et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 2010;28:2423-2429.
15. Coombes RC, Kilburn LS, Snowdon CF et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 2007;369:559-570.
16. Howell A, Cuzick J, BaumMet al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365:60-62.
17. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-1542.
18. Cuzick J, Forbes J, Edwards R et al. First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 2002;360:817-824.
19. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371-1388.
20. Hershman DL, Kushi LH, Shao T et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010;28:4120-4128.
21. Partridge AH, Wang PS, Winer EP et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21: 602-606.
22. Benner JS, Glynn RJ, Mogun H et al. Longterm persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-461.
23. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-497.
24. Leventhal H, Nerenz DR, Leventhal EA et al. The behavioral dynamics of clinical trials. Prev Med 1991;20:132-146.
25. Urquhart J. Compliance and clinical trials. Lancet 1991;337:1224-1225.
26. Balkrishnan R. Predictors of medication adherence in the elderly. Clin Ther 1998;20:764-771.
27. Sharkness CM, Snow DA. The patient's view of hypertension and compliance. Am J Prev Med 1992;8:141-146.
28. Monane M, Bohn RL, Gurwitz JH et al. Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med 1994; 154:433-437.
29. Barat I, Andreasen F, Damsgaard EM. Drug therapy in the elderly: What doctors believe and patients actually do. Br J Clin Pharmacol 2001;51: 615-622.
30. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 1990;150:841-845.
31. Coons SJ, Sheahan SL, Martin SS et al. Predictors of medication noncompliance in a sample of older adults. Clin Ther 1994;16:110-117.
32. Lichtman SM, Wildiers H, Launay-Vacher V et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007;43:14-34.
33. FarmacotherapeutischKompas.2011.18-2-2011. Available at http://fk.cvz.nl, accessed June 1, 2011.
34. Ziller V, Walder M, Albert US et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009; 20(3):431-436.